AlfaKinetic
by Anervea
LandscapeMonitorCompareProfileAsk
principle

Nothing is shown without a source. When the data can’t answer, the product says so.

LB Pharmaceuticals
tenant
person

MapLight Therapeutics

as of 2026-07-01
Monitor thisAsk about this
at a glance
Roles: Study Director
Synthesized from structured facts only — each point cited above.

Profile

Affiliation
MapLight Therapeutics
Roles
Study Director
Trial investigator
no

Trials led

4
A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia
NCT07459647Phase 2Recruiting
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
NCT06887192Phase 2Recruiting
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia
NCT07038876Phase 2Active Not Recruiting
An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis
NCT07459660Phase 2Recruiting

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
STUDY_DIRECTOR
A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia
trial
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
trial
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia
trial
An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis
trial